Evidence map›Paper›PMID 33218310›Full record

ArticleBMC family practice2020

Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design.

Johannes Boettcher, Bonnie Filter, Jonas Denecke, Amra Hot, Anne Daubmann, Antonia Zapf, Karl Wegscheider, Jan Zeidler, J-Matthias Graf von der Schulenburg, Monika Bullinger and 3 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC family practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04339465 naunknown statusnot on this map

Children Affected by Rare Disease and Their Families Network

TypeinterventionalSponsorSilke Wiegand-Grefe, Prof. Dr.Ran2019 to 2022Enrolled687ConditionsRare DiseasesArmsCARE-FAM, WEP-CARE
NCT06548022 nacompletednot on this mapstarted 2024, after this paper: background citation

Rare Group Problem Management Plus

TypeinterventionalSponsorChildren's National Research InstituteRan2024 to 2025Enrolled8ConditionsAnxiety, Depressive Symptoms, Post-traumatic Stress Disorder, Problems PsychosocialArmsRare Group Problem Management Plus
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Being the Pillar for Children with Rare Diseases-A Systematic Review on Parental Quality of Life.International journal of environmental research and public health · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Johannes BoettcherDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. j.boettcher@uke.de.ORCID 0000-0001-9250-2494
Bonnie FilterDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jonas DeneckeDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Amra HotDepartment of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anne DaubmannDepartment of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Antonia ZapfDepartment of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Karl WegscheiderDepartment of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan ZeidlerCenter for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover, Germany.
J-Matthias Graf von der SchulenburgCenter for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover, Germany.
Monika BullingerInstitute for Medical Psychology, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Miriam RassenhoferDepartment of Child- and Adolescent Psychiatry and Psychotherapy, Ulm University Hospital, Ulm, Germany.
Michael Schulte-MarkwortDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Silke Wiegand-GrefeDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DELeibniz University Hannover · DEUniversity Hospital Ulm · DE

Funding

Federal Joint Committee (GB-A) 01NVF17028
6 · The paper itself

Abstract

backgroundFamilies of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at risk for mental disorders, the evaluation of special programs under high methodological standards has not been conducted so far. Moreover, the implementation of interventions for this group into regular care has not yet been accomplished in Germany. The efficacy and cost-effectiveness of a family-based intervention will be assessed. METHODS/

designThe study is a 2x2 factorial randomized controlled multicenter trial conducted at 17 study centers throughout Germany. Participants are families with children and adolescents affected by a rare disease aged 0 to 21 years. Families in the face-to-face intervention CARE-FAM, online intervention WEP-CARE or the combination of both will be treated over a period of roughly 6 months. Topics discussed in the interventions include coping, family relations, and social support. Families in the control condition will receive treatment as usual. The primary efficacy outcome is parental mental health, measured by the Structured Clinical Interview for DSM-IV (SCID-I) by blinded external raters. Further outcomes will be assessed from the parents' as well as the children's perspective. Participants are investigated at baseline, 6, 12 and 18 months after randomization. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed. DISCUSSION: This paper describes the implementation and evaluation of two family-based intervention programs for Children Affected by Rare Disease and their Family's Network (CARE-FAM-NET) in German standard care. A methodologically challenging study design is used to reflect the complexity of the actual medical care situation. This trial could be an important contribution to the improvement of care for this highly burdened group.

trial registrationGerman Clinical Trials Register: DRKS00015859 (registered 18 December 2018) and ClinicalTrials.gov : NCT04339465 (registered 8 April 2020). Protocol Version: 15 August 2020 (Version 6.1). Trial status: Recruitment started on 1 January 2019 and will be completed on 31 March 2021.

Indexed as

FamilyRare DiseasesAdolescentChildHumansMulticenter Studies as TopicParentsRandomized Controlled Trials as TopicResearch DesignTreatment OutcomeFamily interventionInternet-based interventionMental healthRandomized controlled trialRare diseases

Identifiers

PMID33218310
PMCPMC7678588
OpenAlexW3098003990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.